Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie ABBV shares are down 12.4%. In a statement ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part ...

The other possibility is that M1 agonism is required for muscarinic drugs to work and this ... The best-case scenario would ...

was the main focus AbbVie's acquisition of Cerevel, which closed earlier this year. The setback is a potential plus for Bristol Myers Squibb, which in September won Food and Drug Administration ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The rapidly growing aging population is driving expansion in healthcare, with rising demand for treatments and chronic disease management. Companies like AbbVie (ABBV), Medtronic (MDT), and Centene ...